文献速递药物相互作用特殊人群用药

吉瑞替尼的药代动力学特征:一种新型FLT3酪氨酸激酶抑制剂

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
PubMed 文献 · Clin Pharmacokinet · 2020-01-01

本文基于五项临床研究描述吉瑞替尼的临床药代动力学。每日一次给药(20-450 mg)呈剂量比例药代动力学,中位达峰时间2-6小时,平均消除半衰期113小时,主要经粪便排泄。食物不影响暴露;强CYP3A抑制剂/诱导剂显著影响暴露;肝损伤者游离药物暴露与肝功能正常者相似,无需调整剂量。

要点

  • 吉瑞替尼20-450 mg每日一次呈剂量比例药代动力学,半衰期约113小时。
  • 强CYP3A抑制剂或诱导剂显著改变吉瑞替尼暴露,需关注相互作用。
  • 肝损伤患者游离吉瑞替尼暴露与肝功能正常者相似,无需调整剂量。

核心结论

  • 吉瑞替尼在健康受试者和复发/难治性急性髓系白血病患者中呈剂量比例药代动力学。
  • 食物不显著影响吉瑞替尼暴露。
  • 中至强CYP3A抑制剂对吉瑞替尼暴露有显著影响。
  • 吉瑞替尼与CYP3A4或MATE1底物合用不影响底物浓度。
  • 肝损伤患者游离吉瑞替尼暴露与肝功能正常者相当,无需调整剂量。

研究设计与样本

  • 基于五项临床研究评估吉瑞替尼的药代动力学特征。
  • 给药方案为每日一次吉瑞替尼,剂量范围20-450 mg。

主要发现

  • 每日一次吉瑞替尼(20-450 mg)呈剂量比例药代动力学。
  • 单次和多次给药后中位达峰时间为2-6小时。
  • 平均消除半衰期为113小时。
  • 吉瑞替尼主要经粪便排泄。
  • 空腹和餐后条件下吉瑞替尼暴露相当。

关键数值与推荐

  • 吉瑞替尼主要经细胞色素P450(CYP)3A4代谢。
  • 与伊曲康唑(强P-糖蛋白抑制剂和CYP3A4抑制剂)或利福平(强P-糖蛋白诱导剂和CYP3A诱导剂)合用显著影响吉瑞替尼药代动力学。
  • 与咪达唑仑(CYP3A4底物)或头孢氨苄(多药和毒素外排1底物)合用未观察到临床相关相互作用。
  • 肝损伤受试者与肝功能正常受试者游离吉瑞替尼暴露相似,肝损伤患者无需调整剂量。

临床怎么用

  • 吉瑞替尼服药不受饮食影响,可空腹或餐后服用。
  • 应关注吉瑞替尼与中至强CYP3A抑制剂或诱导剂的相互作用,避免显著改变暴露。
  • 肝损伤患者使用吉瑞替尼无需调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the clinical pharmacokinetic profile of gilteritinib. METHODS: The pharmacokinetic profile of gilteritinib was assessed from five clinical studies. RESULTS: Dose-proportional pharmacokinetics was observed following once-daily gilteritinib administration (dose range 20-450 mg). Median maximum concentration was reached 2-6 h following single and repeat dosing of gilteritinib; mean elimination half-life was 113 h. Elimination was primarily via feces. Exposure to gilteritinib was comparable under fasted and fed conditions. Gilteritinib is primarily metabolized via cytochrome P450 (CYP) 3A4; coadministration of gilteritinib with itraconazole (a strong P-glycoprotein inhibitor and CYP3A4 inhibitor) or rifampicin (a strong P-glycoprotein inducer and CYP3A inducer) significantly affected the gilteritinib pharmacokinetic profile. No clinically relevant interactions were observed when gilteritinib was coadministered with midazolam (a CYP3A4 substrate) or cephalexin (a multidrug and toxin extrusion 1 substrate). Unbound gilteritinib exposure was similar between subjects with hepatic impairment and normal hepatic function. CONCLUSIONS: Gilteritinib exhibits a dose-proportional pharmacokinetic profile in healthy subjects and in patients with relapsed/refractory acute myeloid leukemia. Gilteritinib exposure is not significantly affected by food. Moderate-to-strong CYP3A inhibitors demonstrated a significant effect on gilteritinib exposure. Coadministration of gilteritinib with CYP3A4 or multidrug and toxin extrusion 1 substrates did not impact substrate concentrations. Unbound gilteritinib was comparable between subjects with hepatic impairment and normal hepatic function; dose adjustment is not warranted for patients with hepatic impairment. CLINICAL TRIAL REGISTRATION: NCT02014558, NCT02456883, NCT02571816.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. James AJ, Smith CC, Litzow M, et al. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2020. PMID: 32304015. doi:10.1007/s40262-020-00888-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。